Ãå±±½ûµØ

Latest Major R&D Pipeline

Major R&D Pipeline

(As of August 2, 2024)

  • ¡ñ£ºDevelopment progress from April 2024 onwards

Neurology

Dementia

*You can scroll to the left or right here

¡¡
DiseaseStudyRegionDevelopment Stage
¡¸Leqembi¡¹(lecanemab/BAN2401)¡¡Treatment for Alzheimer’s disease (AD) / anti-Aβ protofibril antibody¡¡In-license (BioArctic AB)¡¡Injection (intravenous infusion, subcutaneous injection)¡¡Joint development with Biogen Inc.
Early AD 301 (Clarity AD) Asia (South Korea) ¡ñ Approval (April 2024)
Europe Submission
(accepted: January 2023)
IV maintenance dosing for early AD (Additional Dosage and Administration) 201£¯301 US ¡ñ Submission (June 2024)
Maintenance dosing of a subcutaneous injection formulation for early AD (Additional Formulation) 301 US ¡ñ Rolling Submission (initiated: May 2024)
Preclinical AD 303 (AHEAD 3-45) Japan/US/Europe ±Ê¢ó
E2814¡¡anti-MTBR tau antibody¡¡Collaboration (University College London)¡¡Injection
Dominantly inherited AD Tau Nexgen JP/US/EU ±Ê¢ò/¢ó
103 US/EU ±Ê¢ñ²ú/¢ò
E2511¡¡TrkA integrated synapse regenerant ±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
AD - US ±Ê¢ñ
E2025¡¡Anti-EphA4 antibody¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡±õ²ÔÂá±ð³¦³Ù¾±´Ç²Ô
AD - US ±Ê¢ñ

Neurological diseases other than dementia

*You can scroll to the left or right here

DiseaseStudyRegionDevelopment Stage
¡¸Fycompa¡¹(perampanel/E2007)¡¡Antiepileptic agent / AMPA receptor antagonist¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô / Injection
Adjunctive therapy for primary generalized tonic-clonic seizures (Additional Indication) 332 China ¡ñ Approval (April 2024)
¡¸Dayvigo¡¹(lemborexant/E2006)¡¡Insomnia treatment / Orexin receptor antagonist¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Insomnia disorder 311 China Submission (accepted: January 2024)
mecobalamin/E0302)¡¡Treatment for Amyotrophic lateral sclerosis (ALS)¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡±õ²ÔÂá±ð³¦³Ù¾±´Ç²Ô
ALS JETALS (IIS) Japan Submission (January 2024)
lorcaserin/E2023¡¡Treatment for Dravet syndrome / serotonin 2C receptor agonist¡¡In-license (Arena Pharmaceuticals)¡¡Oral
Dravet syndrome 304 US ±Ê¢ó
E2086¡¡Orexin receptor agonist¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Narcolepsy - US ±Ê¢ñb
EA4017¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Chemotherapy-induced peripheral neuropathy (Development conducted by EA Pharma) - Japan ±Ê¢ñ

Oncology

¡ù×óÓҤ˥¹¥¯¥í©`¥ë¤Ç¤­¤Þ¤¹

DiseaseStudyRegionDevelopment Stage
¡¸Lenvima/Kisplyx¡¹(lenvatinib/E7080)¡¡Anticancer agent / kinase inhibitor¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
In combination with anti-PD-1 therapy pembrolizumab, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication)
Hepatocellular carcinoma (in combination with transcatheter arterial chemoembolization) / First-line LEAP-012 JP/US/EU/CH ±Ê¢ó
Esophageal carcinoma (in combination with chemotherapy) / First-line LEAP-014 JP/US/EU/CH ±Ê¢ó
Gastric cancer (in combination with chemotherapy) / First-line LEAP-015 JP/US/EU/CH ±Ê¢ó
Head and neck cancer / Second-line LEAP-009 US/EU ±Ê¢ò
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Indication)
Hepatocellular carcinoma - Japan ±Ê¢ñb
¡¸Halaven¡¹(eribulin/E7389)¡¡Anticancer agent / microtubule dynamics inhibitor¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡±õ²ÔÂá±ð³¦³Ù¾±´Ç²Ô
Monotherapy (Additional Formulation)
Liposomal formulation - JP/EU ±Ê¢ñ
In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation)
Liposomal formulation 120 Japan ±Ê¢ñ²ú/¢ò
tasurgratinib/E7090¡¡Anticancer agent / FGFR1, FGFR2, FGFR3 inhibitor¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Biliary tract cancer with FGFR2 gene fusion 201 Japan Submission (December 2023)
Breast cancer - Japan ±Ê¢ñb
farletuzumab ecteribulin£¨FZEC£©/MORAb-202¡¡Anticancer agent / Folate receptor α targeted antibody drug conjugate¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡±õ²ÔÂá±ð³¦³Ù¾±´Ç²Ô
Non-small cell lung cancer 203 US/EU ±Ê¢ò
Ovarian cancer, peritoneal cancer, fallopian tube cancer 205 JP/US/EU ±Ê¢ò
Solid tumors 201 US/EU ±Ê¢ñ/¢ò
BB-1701¡¡Anticancer agent / HER2 targeted antibody drug conjugate¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡±õ²ÔÂá±ð³¦³Ù¾±´Ç²Ô
Breast cancer 205 JP/US ±Ê¢ò
E7386¡¡Anticancer agent / CBP/β-catenin interaction inhibitor¡¡Collaboration (PRISM BioLab)¡¡Oral
Solid tumors (in combination with pembrolizumab) 201 JP/US/EU ±Ê¢ñ²ú/¢ò
Solid tumors - JP/US/EU ±Ê¢ñ
Solid tumors (in combination with lenvatinib) - JP/US/EU ±Ê¢ñb
H3B-6545¡¡Anticancer agent / ERα inhibitor¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Breast cancer (in combination with CDK4/6 inhibitor palbociclib) - US/EU ±Ê¢ñb
E7130¡¡ Anticancer agent¡¡Collaboration (Harvard University)¡¡Injection
Solid tumors - Japan ±Ê¢ñ
E7766¡¡Anticancer agent¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡±õ²ÔÂá±ð³¦³Ù¾±´Ç²Ô
Solid tumors - US/EU ±Ê¢ñb

Global Health

¡ù×óÓҤ˥¹¥¯¥í©`¥ë¤Ç¤­¤Þ¤¹

DiseaseSponsor of studyRegionDevelopment Stage
fosravuconazole/E1224¡¡Antifungal agent / ergosterol synthesis inhibitor¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Eumycetoma
*Supported by GHIT fund
*Eisai is mainly responsible for non-clinical studies and the provision of the investigational drug.
DNDi?Mycetoma Research Center of the University of Khartoum Sudan ±Ê¢òb/¢ó
SJ733¡¡Antimalarial agent / ATP4 inhibitor¡¡Co-development (University of Kentucky)¡¡Oral
Malaria
*Supported by GHIT fund
*Eisai is responsible for the provision of drug substance and formulation manufacturing
University of Kentucky Peru ±Ê¢ò
AWZ1066S¡¡Antifilarial agent / antiwolbachia mechanism Co-development (Liverpool School of Tropical Medicine)¡¡Oral
Lymphatic filariasis
*Supported by the GHIT Fund and Medical Research Council in the UK
*Eisai is responsible for the provision of drug substance and formulation manufacturing
Liverpool School of Tropical Medicine UK ±Ê¢ñ

Gastrointestinal Disorders

¡ù×óÓҤ˥¹¥¯¥í©`¥ë¤Ç¤­¤Þ¤¹

DiseaseStudyRegionDevelopment Stage
MOVICOL/(AJG555)¡¡Chronic constipation treatment / polyethylene glycol preparation¡¡In-license (Norgine)¡¡Oral
Chronic constipation in children under 2 years of age (Additional Dosage and Administration)¡¡(Development conducted by EA Pharma) CT3 Japan ±Ê¢ó
AJM347¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Inflammatory bowel disease (Joint development conducted by EA Pharma with Ensho Therapeutics, Inc) - EU ±Ê¢ñ
EA1080¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Inflammatory bowel disease (Joint development conducted by EA Pharma with Ensho Therapeutics, Inc) - EU ±Ê¢ñ
EA3571¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Metabolic dysfunction-associated steatohepatitis (Development conducted by EA Pharma) - Japan ±Ê¢ñ

Other

¡ù×óÓҤ˥¹¥¯¥í©`¥ë¤Ç¤­¤Þ¤¹

DiseaseStudyRegionDevelopment Stage
dotinurad / FYU-981¡¡Treatment for Hyperuricemia and Gout / selective URAT1 inhibitor¡¡In-license (FUJI YAKUHIN)¡¡Oral
Gout, hyperuricemia - Asia (Philippines)

Submission (September 2023)
Gout 301 China Submission (accepted: January 2024)
E6742¡¡Treatment for Systemic lupus erythematosus / TLR 7/8 inhibitor¡¡±õ²Ô-³ó´Ç³Ü²õ±ð¡¡°¿°ù²¹±ô
Systemic lupus erythematosus 101 Japan ±Ê¢ñ/¢ò
E8001¡¡In house¡¡Injection
Rejection reaction associated with organ transplantation - Japan ±Ê¢ñ